Pharmacogenetics: Clinical response to antiplatelet therapy--how much does genotype count?

Comment

Joana Osório. Nat Rev Cardiol. 2010 Nov.

. 2010 Nov;7(11):597.

doi: 10.1038/nrcardio.2010.146.

No abstract available

Comment on

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Mega JL, et al. Lancet. 2010 Oct 16;376(9749):1312-9. doi: 10.1016/S0140-6736(10)61273-1. Lancet. 2010. PMID: 20801494 Free PMC article.
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC; PLATO investigators. Wallentin L, et al. Lancet. 2010 Oct 16;376(9749):1320-8. doi: 10.1016/S0140-6736(10)61274-3. Lancet. 2010. PMID: 20801498
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Paré G, et al. N Engl J Med. 2010 Oct 28;363(18):1704-14. doi: 10.1056/NEJMoa1008410. Epub 2010 Aug 29. N Engl J Med. 2010. PMID: 20979470 Clinical Trial.